Apraglutide Meets Primary Endpoint for Parenteral Support Reduction in Phase 3 STARS Trial

Positive topline results show apraglutide outperformed placebo for relative change from baseline in actual weekly parenteral support volume at week 24 in adults with SBS-IF.

Related Keywords

,Kishorer Iyer ,Michael Shetzline ,Ironwood Pharmaceuticals ,Mount Sinai ,New Drug Application ,Pediatric Intestine Rehabilitation ,Mount Sinai Hospital ,United European Gastroenterology ,